Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer

Niclosamide, an anthelmintic drug approved by the US Food and Drug Administration against cestodes, is used to treat tapeworm infection. In this study, we show that niclosamide can potentially inhibit signal transducer and activator of transcription 3 (STAT3) in colon cancer cell lines. Combined inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Lingyi, Zheng, Hailun, Hu, Wanle, Zhou, Bin, Dai, Xuanxuan, Zhang, Yi, Liu, Zhiguo, Wu, Xiaoping, Zhao, Chengguang, Liang, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370071/
https://www.ncbi.nlm.nih.gov/pubmed/28367059
http://dx.doi.org/10.2147/OTT.S129449
_version_ 1782518179582443520
author Shi, Lingyi
Zheng, Hailun
Hu, Wanle
Zhou, Bin
Dai, Xuanxuan
Zhang, Yi
Liu, Zhiguo
Wu, Xiaoping
Zhao, Chengguang
Liang, Guang
author_facet Shi, Lingyi
Zheng, Hailun
Hu, Wanle
Zhou, Bin
Dai, Xuanxuan
Zhang, Yi
Liu, Zhiguo
Wu, Xiaoping
Zhao, Chengguang
Liang, Guang
author_sort Shi, Lingyi
collection PubMed
description Niclosamide, an anthelmintic drug approved by the US Food and Drug Administration against cestodes, is used to treat tapeworm infection. In this study, we show that niclosamide can potentially inhibit signal transducer and activator of transcription 3 (STAT3) in colon cancer cell lines. Combined inhibition of epidermal growth factor receptor and STAT3 by erlotinib and niclosamide synergistically induces apoptosis and antiproliferation in colon cancer cell lines. Our findings suggest that erlotinib and niclosamide combination provides an effective therapeutic approach to improving the prognosis of colon cancer.
format Online
Article
Text
id pubmed-5370071
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53700712017-03-31 Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer Shi, Lingyi Zheng, Hailun Hu, Wanle Zhou, Bin Dai, Xuanxuan Zhang, Yi Liu, Zhiguo Wu, Xiaoping Zhao, Chengguang Liang, Guang Onco Targets Ther Original Research Niclosamide, an anthelmintic drug approved by the US Food and Drug Administration against cestodes, is used to treat tapeworm infection. In this study, we show that niclosamide can potentially inhibit signal transducer and activator of transcription 3 (STAT3) in colon cancer cell lines. Combined inhibition of epidermal growth factor receptor and STAT3 by erlotinib and niclosamide synergistically induces apoptosis and antiproliferation in colon cancer cell lines. Our findings suggest that erlotinib and niclosamide combination provides an effective therapeutic approach to improving the prognosis of colon cancer. Dove Medical Press 2017-03-23 /pmc/articles/PMC5370071/ /pubmed/28367059 http://dx.doi.org/10.2147/OTT.S129449 Text en © 2017 Shi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Shi, Lingyi
Zheng, Hailun
Hu, Wanle
Zhou, Bin
Dai, Xuanxuan
Zhang, Yi
Liu, Zhiguo
Wu, Xiaoping
Zhao, Chengguang
Liang, Guang
Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer
title Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer
title_full Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer
title_fullStr Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer
title_full_unstemmed Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer
title_short Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer
title_sort niclosamide inhibition of stat3 synergizes with erlotinib in human colon cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370071/
https://www.ncbi.nlm.nih.gov/pubmed/28367059
http://dx.doi.org/10.2147/OTT.S129449
work_keys_str_mv AT shilingyi niclosamideinhibitionofstat3synergizeswitherlotinibinhumancoloncancer
AT zhenghailun niclosamideinhibitionofstat3synergizeswitherlotinibinhumancoloncancer
AT huwanle niclosamideinhibitionofstat3synergizeswitherlotinibinhumancoloncancer
AT zhoubin niclosamideinhibitionofstat3synergizeswitherlotinibinhumancoloncancer
AT daixuanxuan niclosamideinhibitionofstat3synergizeswitherlotinibinhumancoloncancer
AT zhangyi niclosamideinhibitionofstat3synergizeswitherlotinibinhumancoloncancer
AT liuzhiguo niclosamideinhibitionofstat3synergizeswitherlotinibinhumancoloncancer
AT wuxiaoping niclosamideinhibitionofstat3synergizeswitherlotinibinhumancoloncancer
AT zhaochengguang niclosamideinhibitionofstat3synergizeswitherlotinibinhumancoloncancer
AT liangguang niclosamideinhibitionofstat3synergizeswitherlotinibinhumancoloncancer

Ejemplares similares